Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-03
2007-07-03
Shibuya, Mark L. (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S006900
Reexamination Certificate
active
10267706
ABSTRACT:
This invention characterizes the selective apoptotic activity of specially prepared Alpha 2-HS glycoprotein and fragments thereof. Specifically, Alpha 2-HS glycoprotein which has been overloaded with zinc, as well as fragnents thereof, selectively induce apoptosis in HT-29 (colon cancer), LNCaP (prostate cancer) and Hep G2 (hepatoma) cells while having no effect on CCD 18 Co (normal colon) cells.
REFERENCES:
patent: 5449757 (1995-09-01), Serrero
patent: 5500432 (1996-03-01), Nicolaou
patent: 5550019 (1996-08-01), Reed
patent: 5591717 (1997-01-01), Rojiko
patent: 5604113 (1997-02-01), White
patent: 5624808 (1997-04-01), Thompson
patent: 5639727 (1997-06-01), Little et al.
patent: 5650491 (1997-07-01), Reed
patent: 5656725 (1997-08-01), Chittenden
patent: 5994298 (1999-11-01), Tsai et al.
patent: 6051401 (2000-04-01), Chan et al.
patent: 6946256 (2005-09-01), McKeon et al.
patent: 2003/0044400 (2003-03-01), Yu
patent: WO 86/02651 (1986-05-01), None
patent: 97/31107 (1997-08-01), None
Yang et al., Molecular Cell, 1998, vol. 2, pp. 305-316.
Ikawa et al., Jpn. J. Cancer Res., Jun. 1999, vol. 90, pp. 596-599.
Wang et al., Oncogene, vol. 15 pp. 143-157, Sep. 1997.
Lin, et al., “In Vitro Apoptosis in the Human Hepatoma Cell Line Induced by Transforming Growth Factor B1”, Cancer Research, 52, 385-388 (1992).
Grotendorst, et al., “Attachment of Smooth Muscle Cells to Collagen and their Migration toward platelet-derived growth factor”, Proc. Natl. Acad. Sci. USA, vol. 78, No. 6, pp. 3669-3672 (1991).
Wiley, et al.. “Identification and Characterization of a new Member of the TNF Family that Induces Apoptosis”, Immunity vol. 3, 673-682 (1995).
Kawakami. et al., “Cachectin/TNF Kills or Inhibits the Differentiationof 3T3-L1 Cells According to Developmental Stage”, J. of Cellular Physiology 138:1-7 (1989).
Krammer, et al., Apoptosis in the APO-1 system, Apoptosis: The Molecular Basis of Cell Death pp. 87-99 (1991).
von Bulow, et al., “Human fetuin/a,HS glycoprotein in colloid and parenchymal cells in human fetal pituitary gland”, Histochemistry, (1993) 99:13-22.
Grant, et al., “Effects of Epidermal Growth Factor, Fibroblast Growth Factor, and Transforming Growth Factor-B on Cornmeal Cell Chemotaxis”, Investigative Ophthalmology & Visual Science, vol. 33, No. 12 1992).
Yang, et al., “Human a-HS-glycoprotein/bovine fetuin homologue identification and development regulation of the gene”, Biochemica et Biophysica Acta 1130 (1992) 149-156.
Dziegielewska, K.M., et. al., Fetuin, p. 16-17, (R.G. Landes Co.1995).
Dziegielewska, K.M., et. al., Fetuin, “Structure of the Fetuins,” Chap. 2, p. 11-42 (R.G. Landes Co.1995).
Yoshioka, et al., The Completer Amino Acid Sequence of the A-chain of Human Plasma a HS-glycoprotein, The Journal of Biological Chemistry, vol. 261, No. 4, pp. 1665-1676 (1986).
Gejyo, et al., “Characterization of the B-Chain of Human Plasma azHS-Glycoprotein”, The Journal of Biological Chemistry, vol. 258 No. 8, pp. 4966-4971 (1983).
Kerr, J.F.R. and Searle, J., A Suggested Explanation for the Paradoxically slow growth rate of basal-cell Carcinomas . . . , J. Path., vol. 107, p. 41-44, (1971).
Michaelson, J., Cell Selection in Development, Biol. Rev. (1987), vol. 62, p. 115-139, Great Britain.
Wyllie, A.H., et. al., Cell Death: The Significance of Apoptosis, International Review of Cytology, vol. 68, p. 251-306, Academic Press, 1980.
Cope, F., et. al., Apoptosis: The Molecular Basis of Cell Death, Cold Spring Harbor Laboratory Press, p. 61-86, 1991: Carciogenesis and Apoptosis: Paradigms . . . .
Schmid, K., and Burgi, W. (1961) Biochim. Biophys. Acta 47, 440-453.
Ashton BA, Smith R. Plasma α2-HS glycoprotein concentration in Paget's disease of bone: its possible significance. Clin Sci 1980; 58:435-438.
Kalabay L. Cseh K, Benedek S et al. Serum α2-HS glycoprotein concentration in patients with hematological malignancies. A follow-up study. Ann Hematol 1991; 63:264-269.
Schelp FP, Thanangkul O, Supawan V et al. α2-HS-glycoprotein serum levels in protein-energy malnutrition. Br J Nutr 1980; 43:381-383.
Abiodun PO, Ihongbe JC, Dati F. Decreased levels of α2-HS-glycoprotein in children with protein-energy-malnutrition. Eur J Pediatr 1985; 144:368-369.
Abiodun PO, Olomu IN. Serum α2-HS-glycoprotein levels in neonatal infections. Biol Neonate 1991; 60:114-117.
Baskies, et al. “Serum glycoproteins in cancer patients”. Cancer, v. 45, pp. 3050-3060 (1980).
Spiro, “Studies on fetuin, a glycoprotein of fetal serum”. Journal of Biological Chemistry, v. 235, No. 10, pp. 2860-2869 (1960).
Su, et al. Abstract 1257, FASEB Journal, v. 8, No. 4, p. A218 (1994).
Ambryx Biotechnology, Inc.
Shibuya Mark L.
Trojan Law Office
LandOfFree
Alpha 2HS glycoprotein for treatment of cancer and a method... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha 2HS glycoprotein for treatment of cancer and a method..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha 2HS glycoprotein for treatment of cancer and a method... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3740008